PhRMA Wary Of Signals That FDA Eying Parallel Review To Lower Drug Prices

The Pharmaceutical Research and Manufacturers of America is worried by new signals that FDA may try to engage CMS earlier in FDA's drug review process, saying that kind of parallel review is more appropriate for devices that have to meet different evidentiary standards for each agency. FDA does not have a role in drug pricing and it would be concerning if the agency were to involve itself situations where pricing standards were discussed, a PhRMA official told Inside Health Policy...